All In Biotech

NDA 021598 · Harrow Eye

Vigamox

Moxifloxacin Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jun 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Apr 15, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

648

93 Phase 3, 31 recruiting

FAERS reports

6,747

5,884 serious, 767 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 22, 2026.

VIGAMOX ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. VIGAMOX is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* , Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group , Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. ( 1 )

Mechanism: Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology ( 12.4 )] .

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VIGAMOX · MOXIFLOXACIN HYDROCHLORIDE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1

Clinical trials

Interventional ClinicalTrials.gov studies with "Moxifloxacin" as an intervention, any sponsor and status, largest first.

All 648 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma1,340
  • drug hypersensitivity1,158
  • dyspnoea1,134
  • off label use1,078
  • pain1,069
  • wheezing1,018
  • pneumonia968
  • rash908
  • vomiting881
  • drug ineffective840
  • fatigue752
  • malaise731

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200567
2006112
200769
200842
200955
2010101
2011104
2012210
2013127
2014195
2015167
2016240
2017272
2018334
2019365
2020464
2021455
2022574
2023720
2024787
2025741
2026514

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vigamox (Moxifloxacin HCl)

2024 spending

$119K

Beneficiaries

227

489 claims

Per beneficiary

$524

$60.70 per unit

View as table
YearSpending
2020$0
2021$12,775
2022$185,954
2023$167,182
2024$119,019

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 849 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.